Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2015
At a glance
- Drugs LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 15 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 15 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.